drug-eluting stent

Imagine a scaffold that not only holds a wall open but also paints on a coat of paint that stops moss from growing back. A drug-eluting stent does this inside an artery: it props the vessel open like any stent, but its surface is coated with a medication that is slowly released to discourage the scar-like overgrowth that can re-narrow the artery.

After a stent is placed, the body can respond by overgrowing smooth-muscle and scar tissue inside it — a process called in-stent restenosis that gradually clogs the channel again. Drug-eluting stents carry an antiproliferative drug (such as sirolimus or everolimus) held in a thin polymer coating. Over weeks the drug diffuses into the surrounding wall and damps down this excess tissue growth, sharply lowering the chance of re-narrowing compared with bare-metal stents.

Because a stent surface that has not yet healed over can attract clots, patients typically take dual antiplatelet therapy — usually aspirin plus a second agent — for several months to a year. Newer drug-eluting stents heal faster and have shortened the required duration, but the trade-off between clot prevention and bleeding risk remains an individualized judgment.